Gonorrhoeal and Chlamydial Infection

Last updated: August 23, 2025

Overview

Gonorrhoeal and chlamydial infection cannot be differentiated on physical examination

Gonorrhoea vs Chlamydia

GonorrhoeaChlamydia
SymptomsAsymptomatic, itching or burningAsymptomatic, itching or burning
Physical examMucupurulent discharge, cervicitis, motion tendernessMucupurulent discharge, cervicitis, motion tenderness
InvestigationsNAATNAAT
TreatmentAzithromycin or DoxicyclineCeftriaxone + azithromycin
Purulent cervicitis. Differentials can be gonorrheal, chlamydial or trichomonad infection

Gonorrhoeal Infection

Neisseria gonorrhoea is a gram negative coccobacillus that has a propensity to infect the columnar or transitional epithelium at the endocervix and urethra. It may also infect the Bartholin and/or Skene’s glands. Most cases of gonorrheal urethritis/cervicitis are asymptomatic, especially in women. Women with risk factors should be screened regularly for infection.

Neisseria gonorrhoea – gram negative intracellular diplococcus visible inside polymorphonuclear leukocytes
  • Risk factors
    • < 25 years old
    • Presence of other STIs e.g. HIV, syphillis, hepatitis
    • History of gonorrhoeal infection
    • New or multiple sex partners
    • Unprotected sex
    • Commercial sex work
    • Drug use
  • SIgns and symptoms
    • Profuse, odorless, white-yellow vaginal or urethral discharge
    • Dysuria
    • Lower abdominal pain
    • Cervicitis – Hyperemic, edematous endocervical tissue
    • Bartholin cyst
  • Investigation
    • Nucleic Acid Amplification Test for gonorrhea and chlamydia: sample first-void urine or cervical/vaginal discharge (can also get rectal or pharyngeal swabs if there is receptive oral or pharyngeal sex respectively). NAAT is highly sensitive and specific
    • Culture and sensitivity: for antimicrobial resistance
    • Test for other STIs
  • Treatment
    • Single-dose Ceftriaxone and Azithromycin: Azithromycin is added to cover chlamydia and avoid antimicrobial resistance for Neisseria gonorrhoea)
    • Refer sexual partners for treatment or Expedited partner treatment (EPT – the patient gives the prescription to the partner)
    • Abstinence until the patient and sexual partners are treated
  • Complications of gonorrheal infection
    • DIsseminated gonococcal infection (joint pain, septic arthritis commonly in the knee, conjunctivitis)
    • Pelvic inflammatory disease in women
    • Acute epididymitis in males
    • Ophtalmia neonataorum (bilateral conjunctivitis with purulent discharge)

Chlamydial Infection

Chlamydia trachomatis is a gram-negative ovoid non-motile obligate intracellular. It is the 2nd most common non-viral STI after trichomoniasis. All women < 25 years of age and those with high risk should be screened yearly for chlamydia.

  • Risk factors
    • < 25 years old
    • Presence of other STIs e.g. HIV, syphillis, hepatitis
    • History of gonorrhoeal infection
    • New or multiple sex partners
    • Unprotected sex
    • Commercial sex work
    • Drug use
  • Signs and symptoms
    • Mucopurulent discharge
    • Dysuria
    • Lower abdominal pain
    • Cervicitis – Hyperemic, edematous endocervical tissue
  • Investigations
    • Nucleic Acid Amplification Test for gonorrhea and chlamydia: sample first-void urine or cervical/vaginal discharge (can also get rectal or pharyngeal swabs if there is receptive oral or pharyngeal sex respectively). NAAT is highly sensitive and specific
    • Culture and sensitivity: for antimicrobial resistance
    • Test for other STIs
  • Treatment
    • Single-dose Azithromycin can be used alone if gonorrhoea and trichomoniasis is negative
    • Doxycycline 12 hourly for 7 days for anorectal chlamydia
    • Refer sexual partners for treatment or Expedited partner treatment
    • Abstinence until the patient and sexual partners are treated
  • Complications of chlamydia
    • Reactive arthritis: dysuria, monoarthritis of large joints, conjunctivitis/uveitis (can’t see, can’t pee, can’t climb a tree)
    • Pelvic inflammatory disease in women + Fitz-hugh curtis syndrome
    • Acute epididymitis in men
    • Congenital chlamydia (bilateral conjunctivitis with water to purulent discharge 5 – 14 days after birth)
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *